{
    "name": "sodium benzoate/sodium phenylacetate",
    "comment": "Rx",
    "other_names": [
        "Ammonul"
    ],
    "classes": [
        "Urea Cycle Disorder Treatment Agents"
    ],
    "source": "https://reference.medscape.com/drug/ammonul-sodium-benzoate-sodium-phenylacetate-342815",
    "pregnancy": {
        "common": [
            "Available data in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; animal reproduction studies have not been conducted"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on presence of sodium phenylacetate, sodium benzoate in either human or animal milk, effects on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Discontinue oral antihyperammonemic drugs prior to administration",
                "Caution in hepatic/renal impairment, heart failure, sodium retention associated with edema",
                "Avoid repeat loading doses",
                "Nausea/vomiting may occur",
                "Contains 30.5 mg/mL of sodium in undiluted product",
                "Phenylacetate has been associated with neurotoxicity risk",
                "Administration must be through central venous catheter; administration through peripheral line may cause burns; bolus infusion flow rates are relatively high, especially for infants; extravasation into perivenous tissues may lead to skin necrosis; if extravasation is suspected, discontinue infusion and resume at different infusion site, if necessary; monitor infusion site closely for possible infiltration during drug administration; do not administer undiluted product",
                "Due to structural similarities between phenylacetate and benzoate to salicylate, drug may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis; monitoring of blood chemistry profiles, blood pH and pCO",
                "2",
                " should be performed",
                "Because urine potassium loss is enhanced by excretion of non-reabsorbable anions, phenylacetylglutamine and hippurate, plasma potassium levels should be carefully monitored and appropriate treatment given when necessary",
                "Should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema; discontinue administration, evaluate the patient, and institute appropriate therapeutic countermeasures if an adverse event occurs"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "valproic acid",
            "description": {
                "common": "valproic acid decreases effects of sodium phenylacetate by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Valproic acid may exacerbate hyperammonemia in pts. with urea cycle disorders."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxicillin",
            "description": {
                "common": "amoxicillin, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ampicillin",
            "description": {
                "common": "ampicillin, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillin G aqueous",
            "description": {
                "common": "penicillin G aqueous, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillin VK",
            "description": {
                "common": "penicillin VK, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pivmecillinam",
            "description": {
                "common": "pivmecillinam, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid increases levels of sodium phenylacetate by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temocillin",
            "description": {
                "common": "temocillin, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticarcillin",
            "description": {
                "common": "ticarcillin, sodium phenylacetate.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and sodium benzoate both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Vomiting",
            "percent": "12"
        },
        {
            "name": "Acidosis",
            "percent": "3"
        },
        {
            "name": "Agitation",
            "percent": "3"
        },
        {
            "name": "Anemia",
            "percent": "4"
        },
        {
            "name": "Brain edema",
            "percent": "5"
        },
        {
            "name": "Coma",
            "percent": "3"
        },
        {
            "name": "Convulsions",
            "percent": "6"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "DIC",
            "percent": "3"
        },
        {
            "name": "Hyperammonemia",
            "percent": "5"
        },
        {
            "name": "Hyperglycemia",
            "percent": "7"
        },
        {
            "name": "Hypocalcemia",
            "percent": "3"
        },
        {
            "name": "Hypotension",
            "percent": "4"
        },
        {
            "name": "Inj",
            "percent": "3"
        },
        {
            "name": "site reaction",
            "percent": "6"
        },
        {
            "name": "Mental impairment",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "5"
        },
        {
            "name": "Pyrexia",
            "percent": "3"
        },
        {
            "name": "Respiratory distress",
            "percent": "6"
        },
        {
            "name": "Skin disorder",
            "percent": "3"
        },
        {
            "name": "UTI",
            "percent": null
        }
    ]
}